Warning: The NCBI web site requires JavaScript to function. more...
Fetching bibliography...
Generate a file for use with external citation management software.
Fluoride-cleavable, fluorescently labelled reversible terminators: synthesis and use in primer extension.
Knapp DC, Serva S, D'Onofrio J, Keller A, Lubys A, Kurg A, Remm M, Engels JW.
Chemistry. 2011 Mar 1;17(10):2903-15. doi: 10.1002/chem.201001952. Epub 2011 Feb 3.
Similar articles
Fluorescent labeling of (oligo)nucleotides by a new fluoride cleavable linker capable of versatile attachment modes.
Knapp DC, D'Onofrio J, Engels JW.
Bioconjug Chem. 2010 Jun 16;21(6):1043-55. doi: 10.1021/bc900542f.
Synthesis of four colors fluorescently labelled 3'-O-blocked nucleotides with fluoride cleavable blocking group and linker for array based Sequencing-by-Synthesis applications.
Knapp DC, Keller A, D'Onofrio J, Lubys A, Serva S, Kurg A, Remm M, Kwiatkowski M, Engels JW.
Nucleic Acids Symp Ser (Oxf). 2008;(52):345-6. doi: 10.1093/nass/nrn174.
Electrospun polydioxanone-elastin blends: potential for bioresorbable vascular grafts.
Sell SA, McClure MJ, Barnes CP, Knapp DC, Walpoth BH, Simpson DG, Bowlin GL.
Biomed Mater. 2006 Jun;1(2):72-80. doi: 10.1088/1748-6041/1/2/004. Epub 2006 May 4.
Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model.
Knapp DC, Mata JE, Reddy MT, Devi GR, Iversen PL.
Anticancer Drugs. 2003 Jan;14(1):39-47.
Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats.
Arora V, Knapp DC, Reddy MT, Weller DD, Iversen PL.
J Pharm Sci. 2002 Apr;91(4):1009-18.
Opportunistic testing of medically underserved women for cervical cancer in South Africa.
van Bogaert LJ, Knapp DC.
Acta Cytol. 2001 May-Jun;45(3):313-6.
c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity.
Arora V, Knapp DC, Smith BL, Statdfield ML, Stein DA, Reddy MT, Weller DD, Iversen PL.
J Pharmacol Exp Ther. 2000 Mar;292(3):921-8.
Cytological screening for cervical cancer--what are its opportunity costs?
S Afr Med J. 1997 May;87(5):618-9; author reply 619-20. No abstract available.
Filters: Manage Filters